Next Article in Journal
Saussurea involucrata Cultures for High-Altitude Illness: Enhancing Hypoxia Tolerance and Protecting Against Acute/Chronic Hypoxic Injury
Previous Article in Journal
Exploring the Immunomodulatory Effects of Agaricus bisporus Strains Using In Vitro and In Vivo Murine Models
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 18
Issue 4
10.3390/nu18040555
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Using Plant-Derived Polysaccharides in the Management of Cognitive Disorders: Molecular and Clinical Perspectives

by
Yandong Li
1,
Linlin Du
2,†,
Mengyuan Wang
3,†,
Xingyu He
2,
Zongsuo Liang
1,3,* and
Jingling Liu
2,*
1
School of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang 712046, China
2
College of Sciences, Northwest A&F University, Xianyang 712100, China
3
School of Life Science and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Nutrients 2026, 18(4), 555; https://doi.org/10.3390/nu18040555
Submission received: 13 December 2025 / Revised: 26 January 2026 / Accepted: 27 January 2026 / Published: 7 February 2026
(This article belongs to the Section Carbohydrates)
Browse Figures
Versions Notes

Abstract

Background: Cognitive disorders are a class of neurological diseases characterized by declines in cognitive function, imposing a heavy physical and mental burden on middle-aged and elderly individuals. Since the underlying mechanisms of cognitive disorders are not yet fully understood, and different types of cognitive disorders may involve distinct mechanisms, the development of drugs with multi-target therapeutic and preventive effects is of great significance. Currently approved drugs for Alzheimer’s disease, such as acetylcholinesterase inhibitors and NMDA receptor antagonists, show limited efficacy and poor prognosis, highlighting the urgent need for safe and effective alternative treatments. Methods: Plant-derived polysaccharides (PDPs) possess antioxidant, anti-inflammatory, neuroprotective, and immunomodulatory activities, and polysaccharides derived from traditional Chinese medicine, in particular, show great potential for treating cognitive disorders. In recent years, interventions with plant polysaccharides that modulate the gut microbiota to affect the “gut–brain axis” and improve cognitive function have become an emerging research focus. Clinical evidence has also increasingly supported the beneficial effects of polysaccharides on cognitive disorders. Therefore, this study focuses on plant polysaccharides in the intervention of cognitive disorder-related diseases, including both in vivo and in vitro experiments, and summarizes existing findings according to different mechanisms of action. Results and Conclusions: Relevant clinical reports are incorporated to provide a theoretical basis and strong support for the development of polysaccharide-based interventions and new drug development for cognitive disorders.

1. Introduction

Cognitive impairment represents a heterogeneous group of neurological disorders. These disorders are characterized by progressive deterioration in memory, executive function, attention, language, and other cognitive domains. The most prevalent forms include Alzheimer’s disease (AD), vascular dementia (VaD), and mild cognitive impairment (MCI). These conditions not only have a profound negative impact on patients’ quality of life but also impose a considerable socioeconomic burden worldwide [1]. With the rapid acceleration of global population aging, the prevalence of age-related cognitive impairment is projected to rise continuously. By 2050, an estimated 152.8 million individuals are expected to be affected [2]. The associated economic costs are primarily attributable to direct medical expenses, productivity loss, and the demand for long-term care [3]. Thus, cognitive impairment has become a pressing global public health issue. Beyond economic implications, affected individuals frequently encounter multidimensional challenges. These include difficulties in social participation, interpersonal relationships, occupational functioning, and overall health status. Despite extensive research efforts, the complex pathophysiological mechanisms underlying cognitive impairment remain incompletely understood. Moreover, currently available pharmacological therapies provide only modest symptomatic relief during the early stages. They do not halt or reverse the progressive trajectory of the disease.
Current pharmacological interventions for cognitive impairment are mainly focused on symptomatic management. The principal therapeutic agents include acetylcholinesterase inhibitors, such as donepezil, and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine. Donepezil can improve cognitive function in patients with mild to moderate impairment. Memantine is mainly prescribed to alleviate cognitive decline and behavioral symptoms in moderate to severe stages. In addition, drugs such as oxiracetam are used as adjuvant therapies to enhance cerebral metabolism. For comorbid symptoms, including depression and hallucinations, antidepressants such as sertraline and low-dose atypical antipsychotics such as risperidone are sometimes employed [4]. Nevertheless, existing drugs suffer from significant limitations. They provide only transient symptomatic relief and do not halt underlying pathological processes, such as neuronal loss and β-amyloid deposition. Their therapeutic efficacy is modest and shows marked interindividual variability, leaving some patients with minimal benefit. Single-target mechanisms are insufficient to address the multifactorial pathophysiology of cognitive impairment, particularly in Alzheimer’s disease. These drugs are also frequently associated with adverse effects, including gastrointestinal disturbances and cardiovascular risks [5]. Furthermore, most approved drugs are indicated exclusively for Alzheimer’s disease. There is limited evidence supporting their use in other subtypes, such as vascular cognitive impairment [6].
These limitations underscore the urgent need for novel therapeutic strategies in the management of cognitive impairment. Specifically, there is a need for interventions that can overcome single-target restrictions, offer favorable safety profiles, and demonstrate broad applicability. In this context, plant-derived polysaccharides (PDPs) have garnered growing attention. They exhibit multi-target mechanisms, a good safety record, and a long history of use in traditional medicine, including Traditional Chinese Medicine [7]. Recent studies have shown that PDPs possess clear neuroprotective effects through multiple pathways. These include anti-inflammatory, antioxidant, anti-apoptotic, and immunomodulatory mechanisms [8,9]. Importantly, PDPs may also provide indirect neuroprotection by modulating the “gut–brain axis.” The critical role of the gut–brain axis in the pathogenesis and progression of neurodegenerative disorders is increasingly recognized [10]. Therefore, this review aims to systematically summarize current evidence regarding the molecular mechanisms and clinical progress of PDPs in the management of cognitive impairment. Particular emphasis is placed on their translational potential, with the goal of providing valuable insights to guide future research.

2. Materials and Methods

2.1. Literature Search Strategy

This review was conducted using a structured literature search strategy to systematically identify and summarize studies investigating the neuroprotective effects of PDPs in the context of cognitive disorders. Literature searches were performed in major electronic databases, including PubMed, Web of Science, and Scopus, covering publications from the past 10 years available up to 1 October 2024.
The search strategy employed combinations of the following keywords: “plant-derived polysaccharides,” “polysaccharides,” “cognitive disorders,” “Alzheimer’s disease,” “neuroprotection,” “gut–brain axis,” “gut microbiota,” “short-chain fatty acids,” “oxidative stress,” and “neuroinflammation.” In addition, the reference lists of all eligible articles were manually screened to identify further relevant studies.

2.2. Inclusion and Exclusion Criteria

Studies were included if they met one or more of the following criteria: (1) in vitro or in vivo experimental studies investigating the effects of PDPs on cognitive function or related neurobiological mechanisms; (2) experimental studies examining the interactions between PDPs, gut microbiota, and the gut–brain axis; and (3) clinical studies or clinical reports evaluating the effects of PDPs on cognitive outcomes.
Studies were excluded if they met any of the following criteria: (1) review articles, conference abstracts, editorials, commentaries, or opinion papers lacking original experimental or clinical data; (2) studies focusing on non-plant-derived polysaccharides (e.g., polysaccharides of animal or microbial origin); (3) studies that did not assess cognitive function, neurological outcomes, or clearly defined neuroprotective mechanisms; (4) studies with insufficient methodological detail or incomplete data that precluded meaningful interpretation.

2.3. Data Extraction and Synthesis

Eligible studies were categorized according to experimental type (in vitro studies, animal studies, or clinical studies) and qualitatively synthesized based on their primary mechanisms of action, including anti-inflammatory effects, antioxidant activity, modulation of neuronal apoptosis, inhibition of protein aggregation, and regulation of gut microbiota and microbial metabolites. Given the substantial heterogeneity in polysaccharide sources, structural characteristics, and experimental designs, a qualitative synthesis approach was adopted, and no quantitative meta-analysis was performed (Figure 1).

3. Overview of Plant-Derived Polysaccharides

3.1. The Structure of Plant-Derived Polysaccharides

Plant-derived polysaccharides (PDPs) are high-molecular-weight biopolymers composed of monosaccharide units linked through glycosidic bonds. These complex carbohydrates are typically classified based on their monosaccharide composition (e.g., glucose, arabinose, galactose, mannose, rhamnose), branching patterns, molecular weight, and solubility [11]. Structurally, PDPs can be linear or branched. They exhibit various degrees of polymerization, which influence their physicochemical and biological properties [12]. Functionally, PDPs serve multiple roles. They can act as structural components, such as cellulose and hemicellulose, or as storage molecules, such as starch and fructans. Importantly, some PDPs function as bioactive constituents with immunomodulatory, antioxidant, and anti-inflammatory activities [13]. It is this latter category that has attracted interest for therapeutic applications, particularly for PDPs extracted from medicinal plants used in Traditional Chinese Medicine (TCM) and other ethnomedical traditions.

3.2. The Function of Plant-Derived Polysaccharides

A wide variety of medicinal plants are rich in bioactive polysaccharides. Prominent TCM preparations include Ganoderma lucidum (Lingzhi), which contains immunostimulatory and neuroprotective polysaccharides, primarily β-glucans [13]. Astragalus membranaceus (Huangqi) produces Astragalus polysaccharides (APS), which exhibit anti-inflammatory and antioxidant properties [14]. Lycium barbarum (goji berry) is rich in Lycium barbarum polysaccharides (LBPs), which have well-documented neuroprotective and cognitive-enhancing effects [15]. Many other PDPs are derived from medicinal plants, including Panax ginseng, Codonopsis pilosula, and Dendrobium officinale. These polysaccharides also hold promise as therapeutic agents with cognitive benefits [16], This highlights the wealth of research and development opportunities in the ethnopharmacology space. PDP-focused research is not confined to TCM. Polysaccharides isolated from other plants, such as Aloe vera, Allium cepa (onion), and Opuntia ficus-indica (prickly pear), also show potential modulatory effects in neurodegeneration [17,18,19]. Plant polysaccharides possess a variety of pharmacological activities. They can enhance immunity, provide neuroprotection, regulate blood glucose, exert antitumor effects, and exhibit antioxidant properties.

3.3. The Relationship of Structure and Function of Plant-Derived Polysaccharides

The biological activity of PDPs is closely linked to their structural features, which are influenced by the extraction and purification methods employed [20,21]. Common extraction techniques include hot water extraction, enzyme-assisted extraction, and ultrasonic or microwave-assisted extraction. Following extraction, purification often involves ethanol precipitation, deproteinization, and chromatographic separation (e.g., ion-exchange or gel-filtration chromatography) [21]. After isolation, the structural and compositional characterization of these polysaccharides can be performed using various analytical techniques. These techniques include monosaccharide composition analysis (e.g., gas chromatography-mass spectrometry, GC-MS), molecular weight determination (e.g., high-performance gel permeation chromatography), and spectroscopic methods (e.g., NMR, FTIR) [21]. However, a major challenge in the field is the lack of standardized protocols, which complicates cross-study comparisons and translational development [22]. Differences in plant source, environmental conditions, and processing techniques can produce polysaccharides with varying bioactivity. This variability may contribute to inconsistent findings across studies and highlights the need for systematic efforts to carefully document the effects of specific PDPs in appropriate experimental model systems (Figure 2).

4. Molecular Mechanisms Governing Pdp-Mediated Neuroprotection

The neuroprotective potential of PDPs is attributed to their ability to interact with multiple molecular targets and biological pathways implicated in cognitive dysfunction. In this section, we summarize key mechanisms through which PDPs may exert therapeutic effects in neurodegenerative diseases (Figure 3).

4.1. The Anti-Inflammatory Effect

Chronic neuroinflammation is prevalent in various cognitive disorders, particularly in Alzheimer’s disease (AD) and vascular dementia (VaD), where overactivation of microglia and astrocytes leads to the release of pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α), resulting in synaptic loss, neuronal death, and impaired neurogenesis [23,24,25,26]. Polysaccharides (PDPs) exert anti-inflammatory effects through multiple mechanisms: they inhibit inflammatory signaling pathways such as NF-κB, MAPK, and TLR4/MyD88 to reduce pro-inflammatory cytokine levels and increase the expression of anti-inflammatory factors such as IL-10, and they modulate glial cell activation to maintain central nervous system homeostasis [27]. Studies have shown that Astragalus polysaccharides improve learning and memory deficits in AD model rats by suppressing NF-κB signaling [28]; Poria cocos polysaccharides reduce IL-1β and TNF-α levels in the hippocampus, alleviating cognitive decline [29]. Dendrobium officinale polysaccharides provide neuroprotection by regulating microglial activation and downregulating IL-1β, TNF-α, IL-6, and IL-10, improving AD-related cognitive deficits [30]. Houshan Dendrobium polysaccharides ameliorate D-galactose-induced cognitive impairment in mice by reducing inflammation [31]. In addition, evaluations using the Y-maze, passive avoidance test (PAT), and Morris water maze (MWM) demonstrated that Lycium barbarum polysaccharides not only decreased NF-κB, TNF-α, IL-1β, and IL-6 levels but also increased IL-4 and IL-10 activity in the cortex, showing significant inhibitory effects on AD phenotypes [32]. In summary, PDPs exhibit prominent neuroprotective and cognitive benefits by regulating inflammatory signaling pathways, modulating glial cell activation, and balancing pro- and anti-inflammatory factors.

4.2. The Antioxidant Effect

Oxidative stress, resulting from the overproduction of reactive oxygen species (ROS) and impaired antioxidant defense, is closely linked to neuronal injury and cognitive decline [33]. PDPs exhibit strong free radical scavenging activity and upregulate endogenous antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx) [34]. For example, LBP treatment can attenuate lipid peroxidation and ROS accumulation in hippocampal neurons, thereby preserving mitochondrial integrity and synaptic function [35]. Polysaccharides from Hyriopsis cumingii improved SOD activity, reduced lipid peroxidation (MDA), and lowered caspase-3 expression in brain tissue, suggesting neuroprotective effects [36]. Polysaccharides from Gynostemma pentaphyllum (GPP1) attenuated Aβ-induced ROS accumulation, lipid peroxidation, and apoptotic markers in PC12 cells. Other examples include antioxidant and cytoprotective activities from Ganoderma lucidum, Saccharina japonica, and Angelica sinensis polysaccharides, which prevented ROS accumulation, preserved mitochondrial function, and reduced apoptosis in cell and animal models [37,38,39,40]. Cynomorium songaricum polysaccharides also conferred resistance to oxidative injury in neuronal cultures [41]. At the molecular level, many of these effects are linked to activation of the Nrf2/HO-1 signaling pathway, which serves as a major regulator of cellular antioxidant responses. Nrf2 (nuclear factor erythroid 2–related factor 2) is a transcription factor that senses oxidative stress and orchestrates the expression of a broad array of cytoprotective genes. Under basal conditions, Nrf2 is sequestered in the cytoplasm by Keap1 (Kelch-like ECH-associated protein 1) and targeted for ubiquitin-mediated degradation. Upon oxidative or electrophilic stress, Nrf2 dissociates from Keap1, translocates into the nucleus, and binds to antioxidant response elements (AREs) in the promoter regions of target genes, including glutathione-related enzymes, HO-1, NADPH quinone oxidoreductase 1, and thioredoxin systems [42]. Nrf2 controls the transcription of various cytoprotective enzymes through the Keap1/Nrf2/ARE axis [43], including glutathione-related enzymes, HO-1, NADPH quinone oxidoreductase 1, and thioredoxin systems. LBPs, for example, have been shown to enhance Nrf2 and HO-1 expression in rodent retinal tissue following ischemic injury, implicating this pathway in its neuroprotective action. By restoring redox balance, PDPs help maintain cellular homeostasis and protect against age-related oxidative damage in the brain, providing an avenue to better cognitive outcomes [44,45].

4.3. Inhibition of Protein Aggregation

Abnormal protein deposition is a key pathological feature of AD and other dementias. For example, Aβ accumulation in the brain and hyperphosphorylation of tau protein can lead to synaptic damage and neuronal loss [30]. Some polysaccharides (PDPs) have been shown to: inhibit excessive Aβ production, promote Aβ clearance, and reduce abnormal tau phosphorylation [44,45]. For instance, Lycium barbarum polysaccharides have been found to decrease Aβ levels and improve cognitive performance in AD mouse models [46]. Hericium erinaceus polysaccharides can ameliorate tau protein deposition, alleviating AD pathology [46]. Schisandra chinensis polysaccharides can regulate metabolites in the hippocampus to inhibit tau protein phosphorylation, reduce acetylcholinesterase activity, and improve Alzheimer’s disease-related deficits [47].

4.4. Inhibit Neuronal Cell Apoptosis

Apoptotic cell death of neurons is a critical contributor to cognitive dysfunction. PDPs can modulate the expression of key regulators of apoptosis, including Bax, Bcl-2, and caspase-3, shifting the balance toward cell survival. Simultaneously, many PDPs activate pro-survival signaling cascades, such as the PI3K/Akt and MAPK/ERK pathways [48]. These pathways are also involved in regulating the expression of brain-derived neurotrophic factor (BDNF), a crucial molecule for synaptic plasticity, learning, and memory [49]. Enhanced BDNF signaling has been observed in animal models treated with PDPs, suggesting their role in promoting neuronal resilience and regeneration [50,51]. These regulatory mechanisms are also often complementary. For example, Cactus-derived polysaccharides can limit ROS accumulation and prevent apoptosis in H2O2-treated PC12 cells, normalizing the Bax/Bcl-2 ratio [52].
While these examples offer a glimpse into the capacity of PDPs for neuroprotection at a molecular level, further work is needed to fully characterize the dynamics of these activities across cognitive disorders and in clinically relevant model systems, informing more targeted interventional efforts.

5. Pdps as Regulators of the Gut–Brain Axis

An emerging area of interest is the influence of PDPs on the gut–brain axis, the bidirectional communication network between the gastrointestinal tract and the central nervous system. Dysbiosis of the gut microbiota has been implicated in neuroinflammation, amyloid deposition, and cognitive impairment.
The biological effects of polysaccharides are largely dependent on their microbiota-mediated metabolism in the host. Because humans lack endogenous enzymes capable of degrading complex polysaccharides, planter natural product derived polysaccharides (PDPs/NPPs) are primarily fermented by the gut microbiota in the colon. Their structural characteristics including monosaccharide composition, glycosidic linkage types, degree of branching, and molecular weight critically determine fermentability, microbial selectivity, and the resulting metabolite profiles. Distinct polysaccharide structures can therefore selectively enrich specific functional microbial taxa, such as Bifidobacterium, Lactobacillus, Faecalibacterium prausnitzii, or Roseburia spp., thereby driving differential production of short-chain fatty acids (SCFAs) and other bioactive metabolites [53]. Plant polysaccharides must reach the colon to be metabolized by the gut micro-biota, which express carbohydrate-active enzymes (CAZymes) that break them down into bioactive metabolites [54,55].
SCFAs generated in response to PDP/NPP fermentation represent a central mechanistic link connecting polysaccharide structure, microbial ecology, and host physiological outcomes. Acetate, propionate, and butyrate not only serve as major energy substrates for intestinal epithelial cells and support oxidative phosphorylation but also activate G protein-coupled receptors such as GPR41 and GPR43, stimulating the secretion of gut hormones including glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Through these pathways, SCFAs regulate appetite, insulin sensitivity, and systemic glucose and lipid homeostasis. In parallel, SCFAs exert immunomodulatory effects by inhibiting histone deacetylase (HDAC) activity, promoting regulatory T cell (Treg) differentiation, suppressing pro-inflammatory cytokine production, and upregulating tight junction proteins, thereby preserving intestinal barrier integrity and limiting chronic low-grade inflammation [54,55].
Along the gut–brain axis, structurally diverse polysaccharides selectively enrich microbial populations involved in γ-aminobutyric acid (GABA) and tryptophan metabolism, leading to changes in SCFAs, GABA, and indole-derived metabolites. These microbial products influence vagal signaling, blood–brain barrier integrity, neuroinflammatory status, and neurotrophic factor expression (e.g., BDNF), thereby shaping metabolic and neuroendocrine outcomes. Collectively, these findings highlight that PDPs/NPPs exert systemic effects not through a single pathway, but via a structure-dependent fermentation process that generates distinct metabolite signals and coordinates multi-organ crosstalk [56,57].
One common marker of microbial imbalance is the Firmicutes/Bacteroidetes (F/B) ratio, which is often elevated in conditions like obesity, inflammation, and neuropsychiatric disorders. Various polysaccharides, including those from Polygonatum sibiricum, Panax ginseng, Astragalus membranaceus, and Dendrobium officinale [58,59,60,61], have been shown in animal studies to normalize the F/B ratio and improve behavioral symptoms. Interestingly, some polysaccharides from Lycium barbarum and Abelmoschus esculentus improved cognitive and emotional outcomes even while increasing the F/B ratio [62,63,64]. These findings suggest that the absolute F/B ratio may not be the primary determinant of host health. Instead, the functional composition of Firmicutes—particularly the enrichment of short-chain fatty acid–producing bacteria such as Roseburia and Faecalibacterium—appears to play a more critical role in mediating beneficial effects.
Polysaccharides from Astragalus, Hippophae rhamnoides, and Prunus persica have been reported to enhance the abundance of these beneficial bacteria and ameliorate cognitive or mood-related deficits in mice [8,65]. At the genus level, increases in Lactobacillus and Bacteroides species are frequently observed after polysaccharide treatment and are associated with neuroprotective effects via anti-inflammatory and antioxidant mechanisms. Other genera such as Coprococcus, Prevotella, and Paraprevotella have also been implicated in mediating the neuroprotective effects of polysaccharides through roles in neurotransmitter metabolism and immune regulation [56,66]. For example, Transplantation of Coprococcus eutactus alleviated depressive-like behaviors induced by chronic restraint stress in mice, prevented synaptic loss and glial inflammation, and shifted tryptophan metabolism from the neurotoxic kynurenine pathway toward serotonin production in both the brain and colon. Mechanistically, Coprococcus eutactus inhibited rate-limiting enzymes in the kynurenine pathway, while restoring colonic goblet cells and mucus secretion. These findings reveal the antidepressant potential of Coprococcus eutactus and its role in linking gut microbiota modulation to neurotransmitter balance [56,66].
Most plant polysaccharides reach the large intestine undigested and are fermented by gut microbes into various metabolites, with SCFAs such as acetate, propionate, and butyrate being among the most prominent [67,68]. These short-chain fatty acids (SCFAs) play vital roles in maintaining gut health, modulating inflammation, supporting the intestinal barrier, and influencing brain function via the gut–brain axis. SCFAs act through several mechanisms, including activation of G-protein-coupled receptors, inhibition of histone deacetylases, and serving as energy substrates [26]. These actions contribute to reduced neuroinflammation, improved cognition, and stabilization of mood in animal models. In most studies published to date, plant polysaccharides increased SCFA levels in the gut, particularly butyrate, which is known for its neuroprotective and anti-inflammatory properties [56,69,70]. Polysaccharides from the leaves of Polygonatum sibiricum (PsPs) were extracted, purified, and characterized, showing a total sugar content of 97.48% and a monosaccharide composition of mannose, rhamnose, galacturonic acid, glucose, xylose, and arabinose at a molar ratio of 6.6:15.4:4.5:8.8:40.7:24. In mice, PsPs treatment modulated the intestinal microbiota, increasing the relative abundance of Firmicutes and Lactobacillus while decreasing Bacteroidetes, Lachnospiraceae, and Bacteroides. Importantly, PsPs significantly increased the levels of short-chain fatty acids (SCFAs), with acetic acid, propionic acid, and butyric acid all elevated. Notably, butyric acid content nearly doubled, rising from 7.3 μg/mL in control mice to 15.2 μg/mL after PsPs treatment. The production of individual SCFAs is influenced by gut microbiota composition. For instance, Bacteroides and Prevotella primarily produce acetate and propionate [71], while Faecalibacterium prausnitzii and Roseburia are major butyrate producers [72]. Beyond SCFAs, other microbial metabolites such as valeric acid, lipid-like molecules, and unsaturated fatty acids have been associated with improved cognitive function after polysaccharide treatment [8,73]. Ganoderma lucidum polysaccharides can improve learning deficits in D-galactose-induced aging mice by altering the distribution of Lactobacillus in the gut and regulating peptidoglycan and secondary bile acid synthesis [74]. Barley polysaccharides can ameliorate mild cognitive impairment in mice via the liver–brain–gut axis. This involves increasing the abundance of gut microbes norank_f_Muribaculaceae and unclassified f_Lachnospiraceae, as well as elevating SCFA levels, particularly butyrate [75]. Cistanche deserticola polysaccharides can improve cognitive function in D-galactose-induced aging mice by restoring gut homeostasis [76]. In some cases, metabolomic shifts included reductions in compounds typically associated with neuropsychiatric medications, suggesting a rebalancing effect on the host metabolome.
Given the growing recognition of the gut–brain axis as a regulator of the pathogenesis of AD, VaD, and other cognitive disorders [77,78], research focused on the targeted modulation of the gut microbiota to achieve beneficial effects through the application of PDPs has clear value as a direction for further study. However, most existing studies are limited by small sample sizes, short intervention durations, heterogeneous outcome measures, and the inconsistent composition of PDP preparations.

6. Clinical Prospects

Human clinical evidence for the potential benefits of plant-derived polysaccharides (PDPs) has begun to emerge (Table 1). For example, in individuals with subjective cognitive impairment (SCI), Tremella fuciformis-derived polysaccharides were evaluated in an 8-week randomized, double-blind, placebo-controlled trial, in which supplementation was associated with improvements in subjective memory complaints and selected domains of short-term memory and executive function, without significant differences in adverse event rates compared with placebo [79]. Exploratory neuroimaging analyses further suggested region-specific gray matter volume changes in cognition-related brain areas. Despite these encouraging findings, the study was limited by a relatively small sample size, short intervention duration, and the exploratory nature of some outcome measures. In addition, Lycium barbarum polysaccharide (LBP), the major bioactive component of Lycium barbarum, has been evaluated as a gut microbiota-targeted intervention in patients with non-alcoholic fatty liver disease (NAFLD) in a randomized, double-blind, placebo-controlled trial. Fifty NAFLD patients diagnosed by abdominal ultrasonography, laboratory assessments, and questionnaires were randomly assigned to receive either LBP or maltodextrin placebo capsules for 3 months. The primary outcome was improvement in serum alanine aminotransferase (ALT) levels, while secondary outcomes included changes in gut microbiota composition and diversity, intestinal permeability, body composition, treatment compliance, and adverse events. This study provides preliminary evidence supporting the feasibility and short-term safety of LBP supplementation for modulating gut microbiota in NAFLD patients [80,81].
Overall, these findings suggest that PDPs may have potential clinical benefits in both cognitive and metabolic disorders, but the limited sample sizes, short intervention durations, and heterogeneity of outcome measures highlight the need for further well-powered, long-term randomized controlled trials to confirm efficacy and elucidate underlying mechanisms. Moreover, clinical translation must consider regulatory pathways for botanical products, ethical review for human trials, and practical considerations such as patient adherence, formulation stability, and multicenter coordination. Establishing consensus on standardized outcome measures and quality control parameters will facilitate regulatory evaluation and broader clinical adoption.
LBPs are among the most studied PDPs in clinical settings, as evidenced by their robust anti-inflammatory and antidepressive activity in patients affected by nonalcoholic fatty liver disease and subthreshold depression [80,81]. LBP preparations have also exhibited superior efficacy in preclinical models of AD and cognitive decline, but no published trials have specifically tested LBP samples in the management of AD, VaD, or other prominent cognitive disorders. Likewise, while Ganoderma lucidum polysaccharides have been well-validated as safe, hepatoprotective options in healthy volunteers [82], the clinical evidence regarding their performance has been limited. Cordyceps sinensis and Ganoderma lucidum reportedly failed to improve the cognitive function of healthy subjects [83]. The lack of cognitive improvement observed with O. sinensis and G. lucidum supplementation in young healthy participants may be due to the short 30-day intervention, the ceiling effect in cognitively normal individuals, limited sample size, and uncertain bioavailability of active compounds. Additionally, cognitive assessment tools may have been insufficiently sensitive to detect subtle changes in this population. These factors likely contributed to the absence of measurable benefits. And a similarly disappointing results were noted in a study of Ganoderma lucidum spore powder in the context of AD such that patients failed to exhibit improvements in key indices (NPI, ADAS-cog) [84]. The lack of significant effects of Ganoderma lucidum in this pilot study may be due to the short 6-week treatment duration, small sample size, the preliminary design focused on feasibility and safety, and individual variability in disease progression, all of which could limit the detection of cognitive improvements in ADAS-cog, WHOQOL-BREF, and NPI scores. Given the inconsistent formulation of these preparations, limited intervention duration, and variable outcome measures, future research should prioritize the development of standardized extracts, rigorous dosing studies, and longitudinal assessment to determine both efficacy and safety.
Astragalus membranaceus polysaccharides (APS) have been included in several compound formulations evaluated in Chinese clinical studies for memory enhancement and aging-related cognitive decline. For instance, a double-blind, randomized, controlled preliminary study enrolling 61 participants demonstrated the ability of these polysaccharides to mitigate several cognitive symptoms associated with post-stroke fatigue [85]. Clinical trials have been initiated to explore the utility of APS in AD [86], but the results of these trials have yet to be published and will represent an important step toward the commercial implementation of these plant derivatives. Future studies should incorporate standardized APS preparations, longer follow-up durations, and harmonized outcome measures, while also considering regulatory guidance and ethical oversight for trials involving vulnerable populations such as elderly or cognitively impaired patients.
The limitations of this review can be summarized in several aspects. First, the number of available clinical studies is limited, and the sample sizes are generally small, with most enrolling fewer than 100 participants, resulting in limited statistical power [83]. The study durations are also relatively short, which may be insufficient to observe the long-term cognitive benefits or disease-modifying effects of PDPs. Second, the composition and extraction methods of PDP formulations vary across studies and lack standardization, affecting the reproducibility of results and posing challenges for regulatory approval. Third, many studies use compound herbal formulas with complex components, making it difficult to determine the specific contribution of individual PDPs. Finally, data on the long-term safety and pharmacovigilance of PDPs are still insufficient. Overall, these factors limit a comprehensive assessment of the clinical value of PDPs. Overall, these limitations underscore the need for a coordinated research strategy that includes standardization of PDP preparations, rigorous study design, long-term follow-up, and clear consideration of regulatory, ethical, and operational factors to support safe and effective clinical translation.

7. Future Perspectives and Opportunities

While the preclinical and early clinical evidence clearly points to the medicinal utility of PDPs, in line with their long history of traditional use in TCM and other practices throughout the world, a series of issues remain to be addressed to support their broader clinical uptake.
The bioavailability of orally administered PDPs is generally low due to their large molecular size and resistance to digestion (the bioavailability less than 50%) [87]. However, their interaction with gut microbiota leads to fermentation and production of bioactive metabolites such as SCFAs [88], which may mediate systemic and central effects. Still, detailed pharmacokinetic data (including absorption, distribution, metabolism, and excretion [ADME]) are sparse. More studies using labeled compounds or advanced imaging are needed to clarify the pathways by which PDPs or their metabolites exert neuroprotective effects.
Large-scale, randomized, placebo-controlled clinical trials are essential to evaluate the efficacy and safety of standardized PDPs. Trials should target well-defined populations (e.g., MCI, early AD), employ validated cognitive endpoints (e.g., MoCA, ADAS-Cog), and include long-term follow-up. Where possible, biomarker analyses should be integrated to support mechanistic understanding. Furthermore, future research should prioritize addressing key knowledge gaps in a systematic manner: standardization of polysaccharide characterization, optimization of dosage regimens, administration routes, and intervention duration, as well as evaluation of long-term safety and pharmacokinetics. This prioritization will help focus efforts on the most critical areas for clinical translation.
Adoption of modern extraction methods such as ultrasonic-assisted, enzyme-assisted, and supercritical fluid extraction can enhance yield and preserve functional moieties [89]. Structural analysis using multi-dimensional NMR, MALDI-TOF MS, and chromatographic profiling can help define pharmacophores and optimize formulations [90], offering further insights to inform ongoing research and development efforts. Additionally, regulatory, ethical, and practical considerations for clinical translation should be addressed, including ensuring product quality, compliance with guidelines, and feasibility of long-term administration in target populations.

8. Limitations

Despite the growing body of evidence supporting the potential neuroprotective effects of plant-derived polysaccharides, several limitations of the present review should be acknowledged. First, the majority of studies included in this review are based on in vitro experiments and animal models. Although these preclinical studies provide important mechanistic insights, their translational relevance to human cognitive disorders remains uncertain, and the observed effects may not be directly extrapolated to clinical settings.
Second, plant-derived polysaccharides exhibit substantial heterogeneity in terms of botanical origin, extraction methods, molecular weight, monosaccharide composition, and structural features. This heterogeneity complicates direct comparisons across studies and limits the generalizability of the reported findings. Differences in polysaccharide characterization and dosage regimens further contribute to variability in experimental outcomes.
Third, clinical evidence evaluating the efficacy of plant-derived polysaccharides in cognitive disorders remains limited. Most available clinical studies are characterized by small sample sizes, short intervention durations, heterogeneous outcome measures, and insufficient long-term follow-up. As a result, conclusions regarding clinical efficacy should be interpreted with caution.
In addition, the oral bioavailability and pharmacokinetic properties of plant-derived polysaccharides are not yet fully characterized, and long-term safety data are scarce. Inter-individual variability in gut microbiota composition may further influence the metabolic fate and biological activity of polysaccharides, potentially contributing to inconsistent therapeutic responses.
Finally, as a narrative review, this study did not apply a formal quantitative quality assessment or risk of bias scoring system to individual studies, which may introduce selection bias. Future research should prioritize standardized polysaccharide characterization, well-designed randomized controlled trials, and integrative approaches linking polysaccharide structure, gut microbial metabolism, and clinical outcomes.

9. Conclusions

PDPs represent a promising class of natural compounds with the potential to mitigate cognitive decline through diverse mechanisms, including anti-inflammatory, antioxidant, and neuroprotective activities, as well as through the modulation of the gut–brain axis. Polysaccharides from Ganoderma lucidum, Astragalus membranaceus, Lycium barbarum, and other traditional medicinal plants have shown efficacy in animal models, along with encouraging benefits in human trials. Despite their therapeutic promise, challenges related to standardization, bioavailability, and translational validation must be addressed. Advancing the clinical utility of PDPs will require rigorous trials, modern analytical methodologies, and integrative treatment models. As the global burden of cognitive disorders grows, particularly among aging populations, PDPs offer a novel and holistic avenue for intervention. With continued research and development, these complex natural macromolecules could become important tools in the prevention and management of neurodegenerative diseases.

Author Contributions

Writing—original draft, Y.L., L.D., M.W., X.H., Z.L. and J.L.; Writing—review & editing, Y.L., Z.L. and J.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the National Key Research and development pro-gramme-Modernization of traditional Chinese medicine (2024YFC3506402).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Moon, W.; Han, J.W.; Bae, J.B.; Suh, S.W.; Kim, T.H.; Kwak, K.P.; Kim, B.J.; Kim, S.G.; Kim, J.L.; Moon, S.W.; et al. Disease burdens of Alzheimer’s disease, vascular dementia, and mild cognitive impairment. J. Am. Med. Dir. Assoc. 2021, 22, 2093–2099.e3. [Google Scholar] [CrossRef] [PubMed]
  2. Yanez, I.M.; Torres-Cuevas, I.; Corral-Debrinski, M. Neuroglobin: A promising candidate to treat neurological diseases. Neural Regen. Res. 2026, 21, 1292–1303. [Google Scholar] [PubMed]
  3. El-Hayek, Y.H.; Wiley, R.E.; Khoury, C.P.; Daya, R.P.; Ballard, C.; Evans, A.R.; Karran, M.; Molinuevo, J.L.; Norton, M.; Atri, A. Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders. J. Alzheimer’s Dis. 2019, 70, 323–341. [Google Scholar] [CrossRef] [PubMed]
  4. Singh, N.; Hazari, P.P.; Mittal, P.; Yadav, S.K.; Kumar, N.; Mishra, G.; Dahiya, S.; Mishra, A.K. Role of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and psychedelics in the treatment of major depressive disorder: A perspective on mechanistic insight and current status. Eur. J. Pharmacol. 2025, 1001, 177737. [Google Scholar] [CrossRef]
  5. Finn, L. Current medications for the treatment of Alzheimer’s disease: Acetylcholinesterase inhibitors and NMDA receptor antagonist. In Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders; Elsevier: Amsterdam, The Netherlands, 2017; pp. 49–58. [Google Scholar]
  6. Ceyzériat, K.; Zilli, T.; Millet, P.; Frisoni, G.B.; Garibotto, V.; Tournier, B.B. Learning from the past: A review of clinical trials targeting amyloid, tau and neuroinflammation in Alzheimer’s disease. Curr. Alzheimer Res. 2020, 17, 112–125. [Google Scholar] [CrossRef]
  7. Xue, H.; Li, P.; Bian, J.; Gao, Y.; Sang, Y.; Tan, J. Extraction, purification, structure, modification, and biological activity of traditional Chinese medicine polysaccharides: A review. Front. Nutr. 2022, 9, 1005181. [Google Scholar] [CrossRef]
  8. Gao, J.; Liang, Y.; Liu, P. Along the microbiota–gut–brain axis: Use of plant polysaccharides to improve mental disorders. Int. J. Biol. Macromol. 2024, 265, 130903. [Google Scholar] [CrossRef]
  9. Yue, B.; Zong, G.; Tao, R.; Wei, Z.; Lu, Y. Crosstalk between traditional Chinese medicine-derived polysaccharides and the gut microbiota: A new perspective to understand traditional Chinese medicine. Phytother. Res. 2022, 36, 4125–4138. [Google Scholar] [CrossRef]
  10. Loh, J.S.; Mak, W.Q.; Tan, L.K.S.; Ng, C.X.; Chan, H.H.; Yeow, S.H.; Foo, J.B.; Ong, Y.S.; How, C.W.; Khaw, K.Y. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct. Target. Ther. 2024, 9, 37. [Google Scholar] [CrossRef]
  11. Wang, H.; Li, H.; Hou, Y.; Zhang, P.; Tan, M. Plant polysaccharides: Sources, structures, and antidiabetic effects. Curr. Opin. Food Sci. 2023, 51, 101013. [Google Scholar] [CrossRef]
  12. Kabir, S.F.; Rahman, A.; Yeasmin, F.; Sultana, S.; Masud, R.A.; Kanak, N.A.; Haque, P. Occurrence, distribution, and structure of natural polysaccharides. In Radiation-Processed Polysaccharides; Elsevier: Amsterdam, The Netherlands, 2022; pp. 1–27. [Google Scholar]
  13. Lu, J.; He, R.; Sun, P.; Zhang, F.; Linhardt, R.J.; Zhang, A. Molecular mechanisms of bioactive polysaccharides from Ganoderma lucidum (Lingzhi), a review. Int. J. Biol. Macromol. 2020, 150, 765–774. [Google Scholar] [CrossRef] [PubMed]
  14. Chen, G.; Jiang, N.; Zheng, J.; Hu, H.; Yang, H.; Lin, A.; Hu, B.; Liu, H. Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus. Int. J. Biol. Macromol. 2023, 241, 124386. [Google Scholar] [CrossRef] [PubMed]
  15. Chen, W.; Cheng, X.; Chen, J.; Yi, X.; Nie, D.; Sun, X.; Qin, J.; Tian, M.; Jin, G.; Zhang, X. Lycium barbarum polysaccharides prevent memory and neurogenesis impairments in scopolamine-treated rats. PLoS ONE 2014, 9, e88076. [Google Scholar] [CrossRef]
  16. Xu, W.; Zhao, J.; Li, S. Action mechanisms of polysaccharides in Chinese herbal decoctions. Acupunct. Herb. Med. 2025, 5, 1–22. [Google Scholar] [CrossRef]
  17. Wang, Y.; Chen, R.; Yang, Z.; Wen, Q.; Cao, X.; Zhao, N.; Yan, J. Protective effects of polysaccharides in neurodegenerative diseases. Front. Aging Neurosci. 2022, 14, 917629. [Google Scholar] [CrossRef]
  18. Shukla, D.; Jaiswal, A.K.; Suryavanshi, A.; Asati, V.; Mahapatra, D.K.; Kumar, V.; Bharti, S.K. Role of garlic and onion for better cognition and maintenance of neurodegenerative diseases. In Nutraceutical Fruits and Foods for Neurodegenerative Disorders; Elsevier: Amsterdam, The Netherlands, 2024; pp. 333–352. [Google Scholar]
  19. Gan, Q.; Ding, Y.; Peng, M.; Chen, L.; Dong, J.; Hu, J.; Ma, Y. The potential of edible and medicinal resource polysaccharides for prevention and treatment of neurodegenerative diseases. Biomolecules 2023, 13, 873. [Google Scholar] [CrossRef]
  20. Zhao, C.; Li, X.; Miao, J.; Jing, S.; Li, X.; Huang, L.; Gao, W. The effect of different extraction techniques on property and bioactivity of polysaccharides from Dioscorea hemsleyi. Int. J. Biol. Macromol. 2017, 102, 847–856. [Google Scholar] [CrossRef]
  21. Li, X.; Wang, L. Effect of extraction method on structure and antioxidant activity of Hohenbuehelia serotina polysaccharides. Int. J. Biol. Macromol. 2016, 83, 270–276. [Google Scholar] [CrossRef]
  22. Li, L.-F.; Zhang, Q.-W.; Han, Q.-B. Recent advances in qualitative and quantitative analysis of polysaccharides in natural medicines: A critical review. J. Pharm. Biomed. Anal. 2022, 220, 115016. [Google Scholar] [CrossRef] [PubMed]
  23. Ying, C.; Kang, P.; Binkley, M.M.; Ford, A.L.; Chen, Y.; Hassenstab, J.; Wang, Q.; Strain, J.; Morris, J.C.; Lee, J.-M.; et al. Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia. NeuroImage Clin. 2023, 38, 103373. [Google Scholar] [CrossRef]
  24. Leng, F.; Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? Nat. Rev. Neurol. 2021, 17, 157–172. [Google Scholar] [CrossRef]
  25. Hilliard, A.; Mendonca, P.; Soliman, K.F. Involvement of NFƙB and MAPK signaling pathways in the preventive effects of Ganoderma lucidum on the inflammation of BV-2 microglial cells induced by LPS. J. Neuroimmunol. 2020, 345, 577269. [Google Scholar] [CrossRef]
  26. Yang, L.; Han, X.; Xing, F.; Wu, H.; Shi, H.; Huang, F.; Xu, Q.; Wu, X. Total flavonoids of astragalus attenuates experimental autoimmune encephalomyelitis by suppressing the activation and inflammatory responses of microglia via JNK/AKT/NFκB signaling pathway. Phytomedicine 2021, 80, 153385. [Google Scholar] [CrossRef]
  27. Xu, M.; Wang, J.; Zhang, X.; Yan, T.; Wu, B.; Bi, K.; Jia, Y. Polysaccharide from Schisandra chinensis acts via LRP-1 to reverse microglia activation through suppression of the NF-κB and MAPK signaling. J. Ethnopharmacol. 2020, 256, 112798. [Google Scholar] [CrossRef]
  28. Bai, H.; Zhang, Q. Activation of NLRP3 inflammasome and onset of Alzheimer’s disease. Front. Immunol. 2021, 12, 701282. [Google Scholar] [CrossRef]
  29. Li, W.; Shao, C.; Huang, P.; Yu, D.; Yang, J.; Wan, H.; He, Y. Optimization, characterization of Astragalus polysaccharides, and evaluation of anti-inflammation effect in primary cultured astrocytes via HMGB1/RAGE/NF-κB/NLRP3 signal pathway. Ind. Crops Prod. 2023, 197, 116594. [Google Scholar] [CrossRef]
  30. Feng, C.Z.; Cao, L.; Luo, D.; Ju, L.S.; Yang, J.J.; Xu, X.Y.; Yu, Y.P. Dendrobium polysaccharides attenuate cognitive impairment in senescence-accelerated mouse prone 8 mice via modulation of microglial activation. Brain Res. 2019, 1704, 1–10. [Google Scholar] [CrossRef] [PubMed]
  31. Zhang, X.; Ge, R.; Wu, J.; Cai, X.; Deng, G.; Lv, J.; Ma, M.; Yu, N.; Yao, L.; Peng, D. Structural characterization and improves cognitive disorder in ageing mice of a glucomannan from Dendrobium huoshanense. Int. J. Biol. Macromol. 2024, 269, 131995. [Google Scholar] [CrossRef]
  32. Lu, Q.; Meng, Y.; Feng, H.; Di, X.; Guo, X. Evaluation of the Anti-Alzheimer Activity of Lycium barbarum Polysaccharide in Abeta(1-42)-Induced Neurotoxicity in Rat Model. Curr. Issues Mol. Biol. 2025, 47, 226. [Google Scholar] [CrossRef]
  33. Franzoni, F.; Scarfò, G.; Guidotti, S.; Fusi, J.; Asomov, M.; Pruneti, C. Oxidative Stress and Cognitive Decline: The Neuroprotective Role of Natural Antioxidants. Front. Neurosci. 2021, 15, 729757. [Google Scholar] [CrossRef] [PubMed]
  34. Liu, Y.; Sun, Y.; Huang, G. Preparation and antioxidant activities of important traditional plant polysaccharides. Int. J. Biol. Macromol. 2018, 111, 780–786. [Google Scholar] [CrossRef]
  35. Yang, Y.; Yu, L.; Zhu, T.; Xu, S.; He, J.; Mao, N.; Liu, Z.; Wang, D. Neuroprotective effects of Lycium barbarum polysaccharide on light-induced oxidative stress and mitochondrial damage via the Nrf2/HO-1 pathway in mouse hippocampal neurons. Int. J. Biol. Macromol. 2023, 251, 126315. [Google Scholar] [CrossRef]
  36. Hu, C.; Li, J.; Yang, D.; Pan, Y.; Wan, H. A neuroprotective polysaccharide from Hyriopsis cumingii. J. Nat. Prod. 2010, 73, 1489–1493. [Google Scholar] [CrossRef]
  37. Sun, X.Z.; Liao, Y.; Li, W.; Guo, L.M. Neuroprotective effects of Ganoderma lucidum polysaccharides against oxidative stress-induced neuronal apoptosis. Neural Regen. Res. 2017, 12, 953–958. [Google Scholar] [CrossRef] [PubMed]
  38. Guo, S.S.; Cui, X.L.; Rausch, W.D. Ganoderma Lucidum polysaccharides protect against MPP+ and rotenone-induced apoptosis in primary dopaminergic cell cultures through inhibiting oxidative stress. Am. J. Neurodegener. Dis. 2016, 5, 131–144. [Google Scholar]
  39. Olasehinde, T.A.; Olaniran, A.O.; Okoh, A.I. Sulfated polysaccharides of some seaweeds exhibit neuroprotection via mitigation of oxidative stress, cholinergic dysfunction and inhibition of Zn-induced neuronal damage in HT-22 cells. BMC Complement. Med. Ther. 2020, 20, 251. [Google Scholar] [CrossRef]
  40. Lei, T.; Li, H.; Fang, Z.; Lin, J.; Wang, S.; Xiao, L.; Yang, F.; Liu, X.; Zhang, J.; Huang, Z.; et al. Polysaccharides from Angelica sinensis alleviate neuronal cell injury caused by oxidative stress. Neural Regen. Res. 2014, 9, 260–267. [Google Scholar] [CrossRef] [PubMed]
  41. Wang, F.; Liu, Q.; Wang, W.; Li, X.; Zhang, J. A polysaccharide isolated from Cynomorium songaricum Rupr. protects PC12 cells against H2O2-induced injury. Int. J. Biol. Macromol. 2016, 87, 222–228. [Google Scholar] [CrossRef] [PubMed]
  42. Loboda, A.; Damulewicz, M.; Pyza, E.; Jozkowicz, A.; Dulak, J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cell. Mol. Life Sci. 2016, 73, 3221–3247. [Google Scholar] [CrossRef]
  43. Yu, C.; Xiao, J.-H. The Keap1-Nrf2 system: A mediator between oxidative stress and aging. Oxidative Med. Cell. Longev. 2021, 2021, 6635460. [Google Scholar] [CrossRef]
  44. Huang, G.; Mei, X.; Hu, J. The antioxidant activities of natural polysaccharides. Curr. Drug Targets 2017, 18, 1296–1300. [Google Scholar] [CrossRef]
  45. Gao, Q.-H.; Fu, X.; Zhang, R.; Wang, Z.; Guo, M. Neuroprotective effects of plant polysaccharides: A review of the mechanisms. Int. J. Biol. Macromol. 2018, 106, 749–754. [Google Scholar] [CrossRef]
  46. Guan, Y.; Wang, C.; Li, L.; Dai, X.; Liu, Y.; Hsiang, T.; Liu, S.; Wang, D. Structural characterization of Hericium coralloides polysaccharide and its neuroprotective function in Alzheimer’s disease. Int. J. Biol. Macromol. 2024, 277, 133865. [Google Scholar] [CrossRef]
  47. Liu, Y.; Liu, Z.; Wei, M.; Hu, M.; Yue, K.; Bi, R.; Zhai, S.; Pi, Z.; Song, F.; Liu, Z. Pharmacodynamic and urinary metabolomics studies on the mechanism of Schisandra polysaccharide in the treatment of Alzheimer’s disease. Food Funct. 2019, 10, 432–447. [Google Scholar] [CrossRef]
  48. Wang, C.; Duan, X.; Li, H.; Zeng, S.; Yang, Y.; Zhang, W.; Liu, Y.; Ma, W.; Ma, L.; Fan, Y. On the miRNAs-regulated mechanisms by which natural plant polysaccharides control apoptosis. Pharmacol. Res.-Mod. Chin. Med. 2024, 11, 100456. [Google Scholar] [CrossRef]
  49. Wang, C.S.; Kavalali, E.T.; Monteggia, L.M. BDNF signaling in context: From synaptic regulation to psychiatric disorders. Cell 2022, 185, 62–76. [Google Scholar] [CrossRef]
  50. Ma, M.; Quan, H.; Chen, S.; Fu, X.; Zang, L.; Dong, L. The anxiolytic effect of polysaccharides from stellariae radix through monoamine neurotransmitters, HPA axis, and ECS/ERK/CREB/BDNF signaling pathway in stress-induced male rats. Brain Res. Bull. 2023, 203, 110768. [Google Scholar] [CrossRef]
  51. Zhao, S.; Rong, C.; Gao, Y.; Wu, L.; Luo, X.; Song, S.; Liu, Y.; Wong, J.H.; Wang, H.; Yi, L.; et al. Antidepressant-like effect of Ganoderma lucidum spore polysaccharide-peptide mediated by upregulation of prefrontal cortex brain-derived neurotrophic factor. Appl. Microbiol. Biotechnol. 2021, 105, 8675–8688. [Google Scholar] [CrossRef] [PubMed]
  52. Huang, X.; Li, Q.; Li, H.; Guo, L. Neuroprotective and antioxidative effect of cactus polysaccharides in vivo and in vitro. Cell. Mol. Neurobiol. 2009, 29, 1211–1221. [Google Scholar] [CrossRef] [PubMed]
  53. Zhou, F.; Jiang, X.; Wang, T.; Zhang, B.; Zhao, H. Lycium barbarum polysaccharide (LBP): A novel prebiotics candidate for Bifidobacterium and Lactobacillus. Front. Microbiol. 2018, 9, 1034. [Google Scholar] [CrossRef] [PubMed]
  54. Gavande, P.V.; Goyal, A.; Fontes, C.M. Carbohydrates and carbohydrate-active enzymes (CAZyme): An overview. In Glycoside Hydrolases; Elsevier: Amsterdam, The Netherlands, 2023; pp. 1–23. [Google Scholar]
  55. Cabral, L.; Persinoti, G.F.; Paixão, D.A.; Martins, M.P.; Morais, M.A.; Chinaglia, M.; Domingues, M.N.; Sforca, M.L.; Pirolla, R.A.; Generoso, W.C.; et al. Gut microbiome of the largest living rodent harbors unprecedented enzymatic systems to degrade plant polysaccharides. Nat. Commun. 2022, 13, 629. [Google Scholar] [CrossRef]
  56. Sun, Y.; Ho, C.-T.; Zhang, Y.; Hong, M.; Zhang, X. Plant polysaccharides utilized by gut microbiota: New players in ameliorating cognitive impairment. J. Tradit. Complement. Med. 2023, 13, 128–134. [Google Scholar] [CrossRef]
  57. Jiang, Y.; Zeng, X.; Dai, H.; Luo, S.; Zhang, X. Polygonatum sibiricum polysaccharide regulation of gut microbiota: A viable approach to alleviate cognitive impairment. Int. J. Biol. Macromol. 2024, 277, 134494. [Google Scholar] [CrossRef]
  58. Yang, B.; Li, X.; Mesalam, N.M.; Elsadek, M.F.; Abdel-Moneim, A.-M.E. The impact of dietary supplementation of polysaccharide derived from Polygonatum sibiricum on growth, antioxidant capacity, meat quality, digestive physiology, and gut microbiota in broiler chickens. Poult. Sci. 2024, 103, 103675. [Google Scholar] [CrossRef]
  59. Zheng, H.; Ji, H.; Fan, K.; Xu, H.; Huang, Y.; Zheng, Y.; Xu, Q.; Li, C.; Zhao, L.; Li, Y.; et al. Targeting gut microbiota and host metabolism with Dendrobium officinale dietary fiber to prevent obesity and improve glucose homeostasis in diet-induced obese mice. Mol. Nutr. Food Res. 2022, 66, 2100772. [Google Scholar] [CrossRef] [PubMed]
  60. Yu, S.; Chun, E.; Ji, Y.; Lee, Y.J.; Jin, M. Effects of red ginseng on gut, microbiota, and brain in a mouse model of post-infectious irritable bowel syndrome. J. Ginseng Res. 2021, 45, 706–716. [Google Scholar] [CrossRef]
  61. Liu, Y.; Liu, W.; Li, J.; Tang, S.; Wang, M.; Huang, W.; Yao, W.; Gao, X. A polysaccharide extracted from Astragalus membranaceus residue improves cognitive dysfunction by altering gut microbiota in diabetic mice. Carbohydr. Polym. 2019, 205, 500–512. [Google Scholar] [CrossRef] [PubMed]
  62. Hsiao, Y.-K.; Lee, B.-H.; Wu, S.-C. Lactiplantibacillus plantarum-encapsulated microcapsules prepared from okra polysaccharides improved intestinal microbiota in Alzheimer’s disease mice. Front. Microbiol. 2024, 15, 1305617. [Google Scholar] [CrossRef]
  63. Yan, T.; Nian, T.; Liao, Z.; Xiao, F.; Wu, B.; Bi, K.; He, B.; Jia, Y. Antidepressant effects of a polysaccharide from okra (Abelmoschus esculentus (L) Moench) by anti-inflammation and rebalancing the gut microbiota. Int. J. Biol. Macromol. 2020, 144, 427–440. [Google Scholar] [CrossRef]
  64. Zhu, W.; Zhou, S.; Liu, J.; McLean, R.J.; Chu, W. Prebiotic, immuno-stimulating and gut microbiota-modulating effects of Lycium barbarum polysaccharide. Biomed. Pharmacother. 2020, 121, 109591. [Google Scholar] [CrossRef] [PubMed]
  65. Zhao, H.; Liu, J.; Wang, Y.; Shao, M.; Wang, L.; Tang, W.; Wang, Y.; Li, X. Polysaccharides from sea buckthorn (Hippophae rhamnoides L.) berries ameliorate cognitive dysfunction in AD mice induced by a combination of d-gal and AlCl3 by suppressing oxidative stress and inflammation reaction. J. Sci. Food Agric. 2023, 103, 6005–6016. [Google Scholar] [CrossRef]
  66. Xu, L.; Wang, S.; Wu, L.; Cao, H.; Fan, Y.; Wang, X.; Yu, Z.; Zhou, M.; Gao, R.; Wang, J. Coprococcus eutactus screened from healthy adolescent attenuates chronic restraint stress-induced depression-like changes in adolescent mice: Potential roles in the microbiome and neurotransmitter modulation. J. Affect. Disord. 2024, 356, 737–752. [Google Scholar] [CrossRef]
  67. Luo, Y.; Fang, Q.; Lai, Y.; Lei, H.; Zhang, D.; Niu, H.; Wang, R.; Song, C. Polysaccharides from the leaves of Polygonatum sibiricum Red. regulate the gut microbiota and affect the production of short-chain fatty acids in mice. AMB Express 2022, 12, 35. [Google Scholar] [CrossRef]
  68. Lv, H.; Jia, H.; Cai, W.; Cao, R.; Xue, C.; Dong, N. Rehmannia glutinosa polysaccharides attenuates colitis via reshaping gut microbiota and short-chain fatty acid production. J. Sci. Food Agric. 2023, 103, 3926–3938. [Google Scholar] [CrossRef]
  69. Bayazid, A.B.; Jang, Y.A.; Kim, Y.M.; Kim, J.G.; Lim, B.O. Neuroprotective effects of sodium butyrate through suppressing neuroinflammation and modulating antioxidant enzymes. Neurochem. Res. 2021, 46, 2348–2358. [Google Scholar] [CrossRef] [PubMed]
  70. Song, M.; Zhang, S.; Gan, Y.; Ding, T.; Li, Z.; Fan, X. Poria cocos Polysaccharide Reshapes Gut Microbiota to Regulate Short-Chain Fatty Acids and Alleviate Neuroinflammation-Related Cognitive Impairment in Alzheimer’s Disease. J. Agric. Food Chem. 2025, 73, 10316–10330. [Google Scholar] [CrossRef]
  71. Louis, P.; Flint, H.J. Formation of propionate and butyrate by the human colonic microbiota. Environ. Microbiol. 2017, 19, 29–41. [Google Scholar] [CrossRef]
  72. Machiels, K.; Joossens, M.; Sabino, J.; De Preter, V.; Arijs, I.; Eeckhaut, V.; Ballet, V.; Claes, K.; Van Immerseel, F.; Verbeke, K.; et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014, 63, 1275–1283. [Google Scholar] [CrossRef]
  73. Chen, R.; Li, K.; Wang, Y.; Song, L.; Wang, R.; Fan, W.; Zhao, N.; Zou, W.; Yang, Z.; Yan, J. Valeric acid reduction by chitosan oligosaccharide induces autophagy in a Parkinson’s disease mouse model. J. Drug Target. 2024, 32, 423–432. [Google Scholar] [CrossRef] [PubMed]
  74. Chen, Y.; Li, J.; Zhang, S.; Zhao, Y.; Gao, D.; Xu, G. Effects of Ganoderma lucidum polysaccharide on learning and memory impairment and intestinal flora in mice with D-galactose-induced aging. Sci. Nat. 2025, 112, 46. [Google Scholar] [CrossRef] [PubMed]
  75. Fan, M.; Jiang, Y.; Cai, C.; Wang, Z.; Chen, L.; Zhang, X.; Yin, H.; Hu, S.; Liu, J.; Qian, Z.; et al. Barley polysaccharides modulate metabolic and mild cognitive impairment in naturally aging mice through the liver-gut-brain axis. Int. J. Biol. Macromol. 2025, 311, 144008. [Google Scholar] [CrossRef] [PubMed]
  76. Gao, Y.; Li, B.; Liu, H.; Tian, Y.; Gu, C.; Du, X.; Bu, R.; Gao, J.; Liu, Y.; Li, G. Cistanche deserticola polysaccharides alleviate cognitive decline in aging model mice by restoring the gut microbiota-brain axis. Aging 2021, 13, 15320–15335. [Google Scholar] [CrossRef] [PubMed]
  77. Wiatrak, B.; Balon, K.; Jawień, P.; Bednarz, D.; Jęśkowiak, I.; Szeląg, A. The role of the microbiota-gut-brain axis in the development of Alzheimer’s disease. Int. J. Mol. Sci. 2022, 23, 4862. [Google Scholar] [CrossRef]
  78. Solas, M.; Milagro, F.I.; Ramírez, M.J.; Martínez, J.A. Inflammation and gut-brain axis link obesity to cognitive dysfunction: Plausible pharmacological interventions. Curr. Opin. Pharmacol. 2017, 37, 87–92. [Google Scholar] [CrossRef]
  79. Ban, S.; Lee, S.L.; Jeong, H.S.; Lim, S.M.; Park, S.; Hong, Y.S.; Kim, J.E. Efficacy and safety of Tremella fuciformis in individuals with subjective cognitive impairment: A randomized controlled trial. J. Med. Food 2018, 21, 400–407. [Google Scholar] [CrossRef]
  80. Gao, L.-L.; Li, Y.-X.; Ma, J.-M.; Guo, Y.-Q.; Li, L.; Gao, Q.-H.; Fan, Y.-N.; Zhang, M.-W.; Tao, X.-J.; Yu, J.-Q.; et al. Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: Study protocol for a randomized controlled trial. Trials 2021, 22, 566. [Google Scholar] [CrossRef]
  81. Li, X.; Mo, X.; Liu, T.; Shao, R.; Teopiz, K.; McIntyre, R.S.; So, K.-F.; Lin, K. Efficacy of Lycium barbarum polysaccharide in adolescents with subthreshold depression: Interim analysis of a randomized controlled study. Neural Regen. Res. 2022, 17, 1582–1587. [Google Scholar] [CrossRef]
  82. Chiu, H.-F.; Fu, H.-Y.; Lu, Y.-Y.; Han, Y.-C.; Shen, Y.-C.; Venkatakrishnan, K.; Golovinskaia, O.; Wang, C.-K. Triterpenoids and polysaccharide peptides-enriched Ganoderma lucidum: A randomized, double-blind placebo-controlled crossover study of its antioxidation and hepatoprotective efficacy in healthy volunteers. Pharm. Biol. 2017, 55, 1041–1046. [Google Scholar] [CrossRef]
  83. Tsuk, S.; Lev, Y.H.; Rotstein, A.; Carasso, R.; Zeev, A.; Netz, Y.; Dwolatzky, T.; Steiner, G. Clinical effects of a commercial supplement of Ophiocordyceps sinensis and Ganoderma lucidum on cognitive function of healthy young volunteers. Int. J. Med. Mushrooms 2017, 19, 667–673. [Google Scholar] [CrossRef]
  84. Wang, G.-H.; Wang, L.-H.; Wang, C.; Qin, L.-H. Spore powder of Ganoderma lucidum for the treatment of Alzheimer disease: A pilot study. Medicine 2018, 97, e0636. [Google Scholar] [CrossRef] [PubMed]
  85. Liu, C.-H.; Tsai, C.-H.; Li, T.-C.; Yang, Y.-W.; Huang, W.-S.; Lu, M.-K.; Tseng, C.-H.; Huang, H.-C.; Chen, K.-F.; Hsu, T.-S.; et al. Effects of the traditional Chinese herb Astragalus membranaceus in patients with poststroke fatigue: A double-blind, randomized, controlled preliminary study. J. Ethnopharmacol. 2016, 194, 954–962. [Google Scholar] [CrossRef] [PubMed]
  86. Cheng, Y.; Lin, L.; Huang, P.; Zhang, J.; Pan, X. Efficacy, safety, and response predictors of Astragalus in patients with mild to moderate Alzheimer’s disease: A study protocol of an assessor-blind, statistician-blind open-label randomized controlled trial. Contemp. Clin. Trials Commun. 2024, 41, 101339. [Google Scholar] [CrossRef]
  87. Rosales, T.K.O.; da Silva, F.F.A.; Bernardes, E.S.; Fabi, J.P. Plant-derived polyphenolic compounds: Nanodelivery through polysaccharide-based systems to improve the biological properties. Crit. Rev. Food Sci. Nutr. 2024, 64, 11894–11918. [Google Scholar] [CrossRef]
  88. Chen, Y.; Li, H.; Lai, F.; Min, T.; Wu, H.; Zhan, Q. The influence and mechanisms of natural plant polysaccharides on intestinal microbiota-mediated metabolic disorders. Foods 2024, 13, 3882. [Google Scholar] [CrossRef]
  89. Ismail, N.S.A.; Mohamad, M. Ultrasonic Assisted Enzyme Extraction in Plant Extraction: Bioactive Compound. Acta Chem. Malays. (ACMY) 2024, 8, 39–42. [Google Scholar]
  90. Huang, X.; Liu, H.; Lu, D.; Lin, Y.; Liu, J.; Liu, Q.; Nie, Z.; Jiang, G. Mass spectrometry for multi-dimensional characterization of natural and synthetic materials at the nanoscale. Chem. Soc. Rev. 2021, 50, 5243–5280. [Google Scholar] [CrossRef] [PubMed]
Nutrients 18 00555 g001
Figure 1. Literature search workflow.
Figure 1. Literature search workflow.
Nutrients 18 00555 g001
Nutrients 18 00555 g002
Figure 2. The method of extraction and purification of plant polysaccharides.
Figure 2. The method of extraction and purification of plant polysaccharides.
Nutrients 18 00555 g002
Nutrients 18 00555 g003
Figure 3. Molecular mechanisms of plant polysaccharides.
Figure 3. Molecular mechanisms of plant polysaccharides.
Nutrients 18 00555 g003
Table 1. Clinical Evidence for Plant-Derived Polysaccharides in Cognitive and Metabolic Disorders.
Table 1. Clinical Evidence for Plant-Derived Polysaccharides in Cognitive and Metabolic Disorders.
DP SourceStudy DesignPopulationSample SizeIntervention/DoseDurationPrimary OutcomesSecondary OutcomesMain FindingsQuality/Notes
Tremella fuciformisRCT, double-blind, placebo-controlledIndividuals with subjective cognitive impairment (SCI)75Tremella fuciformis polysaccharides8 weeksSubjective memory complaints, short-term memory, executive functionNeuroimaging: region-specific gray matter volume changesImproved subjective memory and selected cognitive domainsSmall sample, short intervention, exploratory outcomes [79]
Lycium barbarum (LBP)RCT, double-blind, placebo-controlledNAFLD patients50LBP or maltodextrin3 monthsSerum ALTGut microbiota com-position/diversity, intestinal permeability, body composition, compliance, adverse eventsFeasible and safe; modulated gut micro-biotaSmall sample, short-term intervention [80]
Lycium barbarumMulti-center/composite outcomesSubthreshold depression, NAFLD29LBP preparations6 weeksInflammatory markers, depression scores-Demonstrated anti-inflammatory and antidepressant activityPreliminary data, limited evidence [81]
Ganoderma lucidumRCT, safety assessmentHealthy volunteers42Polysaccharide preparation6 monthsLiver functionSafety assessmentSafe and hepato-protectiveShort intervention, no cognitive benefit [82]
Cordyceps sinensis & Ganoderma lucidumRCTHealthy young adults96Polysaccharide preparation30 daysCognitive function-No improvement in cognitionShort duration, small sample, possible ceiling effect [83]
Ganoderma lucidum spore powderPilot studyAD patients42Spore powder6 weeksADAS-cog, NPI, WHOQOL-BREF-No significant cognitive improvementSmall sample, short intervention, feasibility study [84]
Astragalus membranaceus (APS)RCT, double-blind, con-trolledPost-stroke fatigue patients61APS-containing compound formulation28 daysCognitive symptoms-Alleviated several cognitive symptomsPreliminary study [85]
APS-containing formulationsClinical trialsAD patients66APS-containing compound24 weeksCognitive indices-Results not yet publishedStudy on-going [86]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Li, Y.; Du, L.; Wang, M.; He, X.; Liang, Z.; Liu, J. Using Plant-Derived Polysaccharides in the Management of Cognitive Disorders: Molecular and Clinical Perspectives. Nutrients 2026, 18, 555. https://doi.org/10.3390/nu18040555

AMA Style

Li Y, Du L, Wang M, He X, Liang Z, Liu J. Using Plant-Derived Polysaccharides in the Management of Cognitive Disorders: Molecular and Clinical Perspectives. Nutrients. 2026; 18(4):555. https://doi.org/10.3390/nu18040555

Chicago/Turabian Style

Li, Yandong, Linlin Du, Mengyuan Wang, Xingyu He, Zongsuo Liang, and Jingling Liu. 2026. "Using Plant-Derived Polysaccharides in the Management of Cognitive Disorders: Molecular and Clinical Perspectives" Nutrients 18, no. 4: 555. https://doi.org/10.3390/nu18040555

APA Style

Li, Y., Du, L., Wang, M., He, X., Liang, Z., & Liu, J. (2026). Using Plant-Derived Polysaccharides in the Management of Cognitive Disorders: Molecular and Clinical Perspectives. Nutrients, 18(4), 555. https://doi.org/10.3390/nu18040555

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop